Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk is taking a page out of Eli Lilly’s playbook as the two GLP-1 drugmakers work to fend off compounding pharmacies ...
Victoza is Novo Nordisk’s once-daily injectable GLP-1 agonist and made around $3.6 billion in sales last year, making it the top-selling drug in the category.
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Pharma group Hikma looks to take advantage as Novo Nordisk’s Wegovy and Ozempic start to go off patent next year ...
Discover the latest experimental obesity drug from Novo Nordisk, achieving 15.7% weight loss after 68 weeks, which fell short of the company's expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results